Roger S. Newton, PhD, FAHA, FACN
Founder, Board Director, and Scientific Advisor Esperion Therapeutics, Inc.
Roger Newton has worked for thirty-five years in the pharmaceutical and biotech life sciences industries. He is currently Founder, Board Director, and Scientific Advisor, at Esperion Therapeutics. He has served as its Executive Chairman and Chief Scientific Officer and also as the first President/CEO. Its business office is in Ann Arbor, MI and formerly had its laboratories in the Michigan Life Science and Innovation Center in Plymouth MI. Prior to his current responsibilities, Roger was Senior Vice President, Pfizer Global R&D, and Director, Esperion Therapeutics, a Pfizer, Inc. company. He was also Co-founder, President/CEO of the original Esperion founded in July 1998. Under Roger's leadership and the team's effort, Esperion raised more than $200 million in venture capital and equity financing, building a portfolio of mechanism-based biopharmaceuticals focusing on HDL therapy and small molecule lipid regulating agents. Esperion was acquired by Pfizer for $1.3 billion in February 2004 and operated as a separate unit within Pfizer until its closure in May 2007. Pfizer then divested Esperion in May 2008 and Roger restarted the company as an independent enterprise. During the past eight years, Tim Mayleben, President/CEO, with Roger, and the Esperion Team have raised over $400 million in venture capital and equity financing to develop ETC-1002 (bempedoic acid) from preclinical into Phase 3 clinical development. ETC-1002 is a novel, once daily, oral drug, which lowers LDL-cholesterol by 20-35% without an increased risk of muscle pain and weakness as observed with statin drugs. Prior to founding the original Esperion, Roger was with Warner Lambert/Parke-Davis from 1981-1998. As a Distinguished Research Fellow and Chairman of the Atherosclerosis Drug Discovery Team, he co-discovered and was the product champion of what is now the largest selling and most prescribed cholesterol-reducing drug in the world, atorvastatin (Lipitor®).
Roger is a member of the Board of Directors of Juventas Therapeutics, Rubicon Genomics, Celsee Diagnostics, Ann Arbor Spark, Groundwork Center for Resilient Communities, the Leelanau Conservancy, and the T.Wall Foundation. He is a member of the National Advisory Boards of the University of Michigan Cardiovascular Center and University of Michigan Life Sciences Institute, and also the Alfred Taubman Research Institute. Roger also participates on the Technology Advisory Boards of Arboretum Ventures, FirstSense Medical, and the Personalized Lifestyle Medicine Institute.
End of main page content.